Drugs / M9466
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06719973 | May 2025 | cancer | EMD Serono Research & Development Institute, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06509906 | Oct 2024 → Dec 2025 | neoplasm | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06421935 | Aug 2024 → Feb 2027 expected | neoplasm | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M9466 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06421935 ↗ |
| Action | Inhibit | “PARP1 Inhibitor M9466” NCT06421935 ↗ |
| Route | Oral | “Participants will be administered M9466 orally.” NCT06421935 ↗ |
| Target | PARP1 | “PARP1 Inhibitor M9466” NCT06421935 ↗ |